{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:28:23Z","timestamp":1792578503653,"version":"4.5.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are multipurpose agents effective in improving glycemic control in patients with type 2 diabetes while also achieving weight loss and risk reduction of major cardiovascular (CV) events and chronic kidney disease progression. With their increased utility in diabetes, obesity, CV health and renal protection, the use of GLP-1RAs has increased. However, with this increased use, there have also been increased reports of associated kidney adverse events, including case reports of acute interstitial nephritis (AIN) associated with GLP-1RA use. We report the data from the Food and Drug Administration adverse event reporting system (FAERS) in relation to GLP-1RA use and adverse kidney events, with acute kidney injury being the most common. In addition, we report two cases of semaglutide-associated biopsy-proven AIN and one with associated podocytopathy. To our knowledge, this is the first case of biopsy-proven AIN with podocytopathy associated with semaglutide use. Both patients experienced complete remission shortly after discontinuing semaglutide and undergoing immunosuppressive therapy. Further analysis of the FAERS database revealed 17 cases of proteinuria and 1 case of glomerulonephritis associated with semaglutide in the FAERS database, however no further information was available. While further research is needed to establish causality, this case series adds to the growing body of literature that semaglutide is associated with AIN and adds a new association, semaglutide with AIN and podocytopathies. While the overall clinical and mortality benefits of GLP-1RAs may outweigh the rarer risks, prescribers need to be aware of these associations, particularly as the use of GLP-1RAs continues to expand.<\/jats:p>","DOI":"10.1093\/ckj\/sfae250","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:42:36Z","timestamp":1723509756000},"source":"Crossref","is-referenced-by-count":33,"title":["Semaglutide-associated kidney injury"],"prefix":"10.1093","volume":"17","author":[{"given":"Farhana","family":"Begum","sequence":"first","affiliation":[{"name":"Northwell Health, New Hyde Park, NY and Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell , Manhasset, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Christus Health\/Texas A&M School of Medicine , Longview, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Christus Health\/Texas A&M School of Medicine , Longview, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Vij","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Christus Health\/Texas A&M School of Medicine , Longview, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Phadke","sequence":"additional","affiliation":[{"name":"Metrolina Nephrology Associates; Atrium Health , Charlotte, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley M","family":"Hiser","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Medical Center, Pathologists Bio-Medical Laboratories , Dallas, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimda","family":"Wanchoo","sequence":"additional","affiliation":[{"name":"Northwell Health, New Hyde Park, NY and Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell , Manhasset, NY , USA"},{"name":"Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell , Great Neck, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purva","family":"Sharma","sequence":"additional","affiliation":[{"name":"Northwell Health, New Hyde Park, NY and Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell , Manhasset, NY , USA"},{"name":"Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell , Great Neck, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirja","family":"Sutaria","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Atrium Health Wake Forest University School of Medicine , Charlotte, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1578-0524","authenticated-orcid":false,"given":"Kenar D","family":"Jhaveri","sequence":"additional","affiliation":[{"name":"Northwell Health, New Hyde Park, NY and Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell , Manhasset, NY , USA"},{"name":"Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell , Great Neck, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"key":"2024091008561390800_bib1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.2337\/ds16-0026","article-title":"Glucagon-like peptide 1 receptor agonists for type 2 diabetes","volume":"30","author":"Hinnen","year":"2017","journal-title":"Diabetes Spectr"},{"key":"2024091008561390800_bib2","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2024091008561390800_bib3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"2024091008561390800_bib4","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2024091008561390800_bib5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2024091008561390800_bib6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev Diabet Stud"},{"key":"2024091008561390800_bib7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1464-5491.2012.03738.x","article-title":"Acute tubulointerstitial nephritis following treatment with exenatide","volume":"30","author":"Nandakoban","year":"2013","journal-title":"Diabet Med"},{"key":"2024091008561390800_bib8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.xkme.2020.10.008","article-title":"Acute kidney injury associated with semaglutide","volume":"3","author":"Leehey","year":"2021","journal-title":"Kidney Med"},{"key":"2024091008561390800_bib9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.15277\/bjd.2021.321","article-title":"Antidiabetic medication-induced acute interstitial nephritis: case report and literature search","volume":"21","author":"Chaudhury","year":"2021","journal-title":"Br J Diabetes"},{"key":"2024091008561390800_bib10","doi-asserted-by":"publisher","first-page":"100561","DOI":"10.1016\/j.xkme.2022.100561","article-title":"Semaglutide-associated acute interstitial nephritis: a case report","volume":"4","author":"Borkum","year":"2022","journal-title":"Kidney Med"},{"key":"2024091008561390800_bib11","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2337\/cd21-0142","article-title":"A case of dulaglutide-induced acute interstitial nephritis after many years of treatment with an alternate GLP-1 receptor agonist","volume":"40","author":"Komala","year":"2022","journal-title":"Clin Diabetes"},{"key":"2024091008561390800_bib12","doi-asserted-by":"publisher","first-page":"e231383","DOI":"10.7326\/aimcc.2023.1383","article-title":"Diffuse podocytopathy associated with semaglutide","volume":"3","author":"Attieh","year":"2024","journal-title":"Ann Intern Med Clin Cases"},{"key":"2024091008561390800_bib13","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/aje\/kwac021","article-title":"Glucagon-like peptide 1 receptor agonists and risk of anaphylactic reaction among patients with type 2 diabetes: a multisite population-based cohort study","volume":"191","author":"Pradhan","year":"2022","journal-title":"Am J Epidemiol"},{"key":"2024091008561390800_bib14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024091008561390800_bib15","doi-asserted-by":"publisher","first-page":"1032199","DOI":"10.3389\/fendo.2022.1032199","article-title":"Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data","volume":"13","author":"Dong","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2024091008561390800_bib16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1053\/j.ajkd.2013.10.057","article-title":"Acute interstitial nephritis after treatment with liraglutide","volume":"63","author":"Gariani","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2024091008561390800_bib17","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1016\/j.diabres.2013.11.014","article-title":"Severe acute renal failure in patients treated with glucagon-like peptide-1 receptor agonists","volume":"103","author":"Dubois-Laforgue","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"2024091008561390800_bib18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/pdi.1493","article-title":"Exenatide associated renal failure","volume":"27","author":"Bhatti","year":"2010","journal-title":"Pract Diabetes Int"},{"key":"2024091008561390800_bib19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/8755122518782155","article-title":"Acute kidney injury occurring in a patient initiated on dulaglutide","volume":"34","author":"Taylor","year":"2018","journal-title":"J Pharm Technol"},{"key":"2024091008561390800_bib20","doi-asserted-by":"publisher","first-page":"e45261","DOI":"10.7759\/cureus.45261","article-title":"An Incidental Finding of a Glucagon-Like Peptide 1 (GLP-1)-Induced Acute Kidney Injury: A Case Report","volume":"15","author":"Aleman Espino","year":"2023","journal-title":"Cureus"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae250\/58813364\/sfae250.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/9\/sfae250\/59069440\/sfae250.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/9\/sfae250\/59069440\/sfae250.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T12:24:20Z","timestamp":1725971060000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfae250\/7733090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfae250","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,8,13]]},"article-number":"sfae250"}}